Xiong Fangfang, Shen Yunzhu, Liu Ting, Zhang Yin, Jiang Xuehui
Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
BMJ Support Palliat Care. 2024 Aug 19. doi: 10.1136/spcare-2024-005113.
Osimertinib plays a crucial role in patients with non-small cell lung cancer (NSCLC). However, the haematological toxicities caused by osimertinib in such a population have not been well characterised. This analysis was performed to determine the incidence of osimertinib-related haematological toxicity in patients with NSCLC.
A literature search was conducted in PubMed, Embase, Cochrane Library and Web of Science. Eligible studies were included to describe the pooled incidences of anaemia, neutropenia and thrombocytopenia secondary to osimertinib in NSCLC patients.
1288 patients from 10 studies were enrolled in this study. The overall incidences of osimertinib-related all-grade anaemia, neutropenia and thrombocytopenia in NSCLC patients were 21.1% (95% CI 10.9% to 33.3%), 14.6% (95% CI 5.9% to 26.1%) and 28.4% (95% CI 12.4% to 47.6%), respectively. In items of high-grade haematological toxicities, there were 0.5% (95% CI 0.1% to 1.1%) for anaemia, 2.0% (95% CI 0.3% to 4.6%) for neutropenia and 0.4% (95% CI 0% to 1.1%) for thrombocytopenia.
There is non-negligible haematological toxicity associated with osimertinib, and it should be taken seriously.
奥希替尼在非小细胞肺癌（NSCLC）患者中发挥着关键作用。然而，奥希替尼在此类人群中引起的血液学毒性尚未得到充分描述。进行本分析以确定NSCLC患者中奥希替尼相关血液学毒性的发生率。
在PubMed、Embase、Cochrane图书馆和Web of Science中进行文献检索。纳入符合条件的研究以描述NSCLC患者中奥希替尼继发的贫血、中性粒细胞减少和血小板减少的合并发生率。
本研究纳入了10项研究中的1288例患者。NSCLC患者中奥希替尼相关的所有级别的贫血、中性粒细胞减少和血小板减少的总体发生率分别为21.1%（95%CI 10.9%至33.3%）、14.6%（95%CI 5.9%至26.1%）和28.4%（95%CI 12.4%至47.6%）。在高级别血液学毒性方面，贫血为0.5%（95%CI 0.1%至1.1%），中性粒细胞减少为2.0%（95%CI 0.3%至4.6%），血小板减少为0.4%（95%CI 0%至1.1%）。
奥希替尼存在不可忽视的血液学毒性，应予以重视。
